SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA. The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therape ...

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA. The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on C ...

Core Viewpoint - Polyrizon Ltd. has initiated preclinical studies for intranasal Benzodiazepines (BZDs) aimed at improving emergency treatment options for acute repetitive seizures and status epilepticus using its proprietary drug delivery platform [1][5][8]. Company Summary - Polyrizon is a development stage biotech company focused on innovative intranasal hydrogels and drug delivery systems, including its Trap and Target™ (T&T) platform for administering BZDs [1][8]. - The company is collaborating with Professor Fabio Sonvico from the University of Parma, an expert in intranasal drug delivery solutions, to conduct these preclinical studies [4]. Industry Summary - The global acute repetitive seizures market was valued at approximately USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030 [2]. - The global epilepsy treatment devices market was valued at around USD 526.8 million in 2023 and is expected to reach approximately USD 787.3 million by 2033, growing at a CAGR of about 4.1% from 2024 to 2033 [3].

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics (“the psychedelic company”), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyri ...

KORU Medical Systems (KRMD) Q4 2024 Earnings Call March 12, 2025 04:30 PM ET Company Participants Louisa Smith - PrincipalLinda Tharby - President and CEOTom Adams - Chief Financial OfficerMichaela Smith - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareFrank Takkinen - Senior Research AnalystJason Bednar - Senior Research AnalystAnderson Schock - Research Analyst Operator Greetings, and welcome to the Coram Medical Systems Fourth Quarter and Ful ...